Navigation Links
OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease
Date:2/25/2009

NEW YORK, Feb. 25 /PRNewswire/ -- OLIGOMERIX, Inc. today announced the receipt of a Small Business Innovation Research (SBIR) Phase I grant for $323,000 from the National Institute on Aging of the National Institutes of Health (NIH). The focus of the program is to develop novel biomarker assays for Alzheimer's disease (AD). Tau oligomers in complex with beta-amyloid or apolipoprotein E (apoE) proteins will be monitored in cerebrospinal fluid (CSF) and plasma from AD patients. The work will be done in collaboration with Drs. Lawrence S. Honig and Richard Mayeux at the Taub Institute for Research on Alzheimer's disease and the Aging Brain at Columbia University Medical Center (CUMC).

There is a critical unmet need for novel biomarkers for AD, both with respect to differential diagnosis of AD at first evaluation, and for monitoring disease progression. Presently, definitive diagnosis of AD can only be accomplished after death, through brain autopsy. There are no validated biomarkers from patient samples such as CSF or plasma that predict progression or regression of AD. OLIGOMERIX plans to evaluate novel AD biomarkers based on the paradigm of protein-protein interactions. This strategy may enable more specific diagnosis and disease monitoring, for better patient management.

"Our focus is to develop assays that can be used for drug discovery for AD," stated James Moe, Ph.D., MBA, President and CEO of OLIGOMERIX "Any validated assays developed under this program for disease staging or definitive diagnosis of AD will be potential out-licensing opportunities for the company."

ABOUT OLIGOMERIX

OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located at Audubon Biomedical Science and Technology Park, CUMC. The Company is developing a drug discovery platform that includes biomarker assays for discovering small molecule inhibitors of tau oligomer formation that are novel AD targets.

For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated. Risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding, contract research, and services.

    CONTACTS:
    OLIGOMERIX, Inc.
    James Moe, President and CEO
    212-568-0365 Ext. 18
    jmoe@oligomerix.com

    Richard Lewis Communications, Inc.
    212-827-0020
    Cecelia Heer, Investors
    cheer@rlcinc.com
    Gregory Tiberend, Media
    gtiberend@rlcinc.com


'/>"/>
SOURCE OLIGOMERIX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peter Zoller and Ignacio Cirac, awarded by the BBVA Foundation
2. Origin BioMed Awarded Red Herring Top 100 Global Company
3. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
4. Eurotech Catalyst Module Awarded to Allen Organ Company From Arrow Electronics
5. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
6. Probiotic Delivery Technology Awarded Third International Patent
7. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
8. China Medicine Corporation Awarded GSP Certification
9. Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission
10. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
11. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... enabling healthier lives through the development of innovative products ... the United States denied its ... the claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 ... criteria established by the Supreme Court,s Mayo Collaborative Services ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
Breaking Biology News(10 mins):